首页> 外文期刊>Bioorganic and medicinal chemistry >Design, synthesis and biological evaluation of imidazole and oxazole fragments as HIV-1 integrase-LEDGF/p75 disruptors and inhibitors of microbial pathogens
【24h】

Design, synthesis and biological evaluation of imidazole and oxazole fragments as HIV-1 integrase-LEDGF/p75 disruptors and inhibitors of microbial pathogens

机译:咪唑和氧唑片段的设计,合成及生物学评价,如HIV-1整合酶-EDGF / P75破坏者和微生物病原体抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

We describe here the synthesis of libraries of novel 1-subtituted-5-aryl-1H-imidazole, 5-aryl-4-tosyl-4,5-dihydro-1,3-oxazole and 5-aryl-1,3-oxazole fragments via microwave (MW)-assisted cycloaddition of para-toluenesulfonylmethyl isocyanide (TosMIC) to imines and aldehydes. The compounds obtained were biologically evaluated in an AlphaScreen HIV-1 IN-LEDGF/p75 inhibition assay with six imidazole-based compounds (16c, 16f, 17c, 17f, 20a and 20d) displaying more than 50% inhibition at 10 mu M, with IC50 values ranging from 7.0 to 30.4 mu M. Additionally the hypothesis model developed predicts all active scaffolds except 20d to occupy similar areas as the N-heterocyclic (A) moiety and two aromatic rings (B and C) of previously identified inhibitor 5. These results indicate that the identified compounds represent a viable starting point for their use as templates in the design of next generation inhibitors targeting the HIV-1 IN and LEDGF/p75 protein-protein interaction. In addition, the in vitro antimicrobial properties of these fragments were tested by minimum inhibitory concentration (MIC) assays showing that compound 16f exhibited a MIC value of 15.6 mu g/ml against S. aureus, while 17f displayed a similar MIC value against B. cereus, suggesting that these compounds could be further developed to specifically target those microbial pathogens.
机译:我们在这里描述了新型1-亚列-5-芳基-1H-咪唑,5-芳基-4-甲苯胺-4,5-二氢-1,3-氧唑和5-芳基-1,3-氧唑的文献的合成通过微波(MW)碎片的碎片 - 甲苯磺酰基甲基异氰化物(TOSMIC)对亚胺和醛的循环加入。获得的化合物在αSEDGF/ P75抑制测定中,含有六种基于咪唑基化合物(16C,16F,17C,17F,20A和20D)在10μM下显示超过50%的抑制作用IC 50值从7.0到30.4 mu m。另外,开发的假设模型预测了除20d以外的所有活性支架,以占据与先前鉴定的抑制剂的N-杂环(a)部分和两个芳族环(b和c)的类似区域5.这些结果表明,所鉴定的化合物代表其用作靶向HIV-1和LEDGF / P75蛋白质 - 蛋白质相互作用的下一代抑制剂的模板的可行起始点。此外,通过最小抑制浓度(MIC)测定来测试这些片段的体外抗微生物性质(MIC)测定,所述化合物16f表现出对金黄色葡萄球菌的MIC值为15.6μg/ ml,而17F针对B的类似MIC值。培养物,表明这些化合物可以进一步开发成特异性靶向那些微生物病原体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号